Rate of venous thromboembolism on an enhanced recovery program after gynecologic surgery

• Published in: American journal of obstetrics and gynecology 2023-08, Vol.229 (2), p.140.e1-140.e7
• Main Authors: Taylor, Jolyn S., Iniesta, Maria D., Zorrilla-Vaca, Andres, Cain, Katherine E., Lasala, Javier D., Mena, Gabriel E., Meyer, Larissa A., Ramirez, Pedro T.
• Format: Article
• Language: English
• Subjects: Enhanced Recovery After Surgery; Female; gynecologic surgery; Gynecologic Surgical Procedures - methods; Heparin; Hospitalization; Humans; Minimally Invasive Surgical Procedures - adverse effects; Postoperative Complications - epidemiology; Postoperative Complications - etiology; venous thromboembolism; Venous Thromboembolism - epidemiology; Venous Thromboembolism - etiology; Venous Thromboembolism - prevention & control
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/j.ajog.2023.04.045

Venous thromboembolism is a life-threatening complication of surgery. An Enhanced Recovery After Surgery program is a multimodal care pathway that facilitates faster recovery from surgery. The rate of venous thromboembolism after gynecologic surgery on an Enhanced Recovery After Surgery program is unknown. This study aimed to evaluate the rate of venous thromboembolism within 30 days of gynecologic surgery on an Enhanced Recovery After Surgery pathway performed at a cancer center. Data were collected prospectively on Enhanced Recovery After Surgery pathway gynecologic patients undergoing open surgery (November 3, 2014, to March 31, 2021) and minimally invasive surgery (February 1, 2017, to March 31, 2021). Care was delivered at a tertiary cancer care center located in a large urban area. Patients undergoing emergency surgery or multispecialty surgeries were excluded. Patients undergoing open surgery were to receive heparin prophylaxis before surgery, sequential compression devices during surgery and admission, and low-molecular-weight heparin prophylaxis during admission. If diagnosed with malignancy, patients were to receive extended venous thromboembolism prophylaxis for 28 days after surgery. For minimally invasive surgery, patients received only sequential compression devices during surgery and no heparin prophylaxis before or after surgery. Venous thromboembolism events were included if detected on imaging obtained for symptoms or other indications. Descriptive statistics and bivariate statistical analyses were performed. Of 3329 patients, 1519 (45.6%) underwent laparotomy, 1452 (43.6%) underwent laparoscopy, and 358 (10.8%) underwent robotic surgery. The incidence rates of venous thromboembolism were 0.6% (n=21; 95% confidence interval, 0.4%–0.9%) overall, 1.1% (n=16, 95% confidence interval, 0.6%–1.7%) in the open approach, and 0.3% (n=5; 95% confidence interval, 0.3%–0.6%) in the minimally invasive approach (P=.02). The incidence rates of venous thromboembolism among the 1999 patients with malignancy were 0.9% (n=18; 95% confidence interval, 0.5%–1.4%) overall, 1.4% (n=15; 95% confidence interval, 0.7%–2.2%) in the open approach, and 0.3% (n=3; 95% confidence interval, 0.1%–0.9%) in the minimally invasive approach. The incidence rates of venous thromboembolism among the 1165 patients with benign disease were 0.3% (n=3; 95% confidence interval, 0.1%–0.7%) overall, 0.3% (n=1; 95% confidence interval, 0.0%–1.7%) in the open approach, and 0.2% (n=2; 95